Register
Investigational Osteoarthritis Drug Results Mixed |
Journal Updates
eMediNexus Coverage from: 
Investigational Osteoarthritis Drug Results Mixed
eMediNexus,  11 October 2019
remove_red_eye 508 Views
#Orthopedics #Pathology and Lab Medicine #Pharmacist #Rheumatology

1 Read Comments                

An injection of the investigational osteoarthritis drug sprifermin into the knee joint every 6 or 12 months resulted in statistically significant improvement in cartilage thickness after 2 years compared with placebo, suggests new research.

However, the authors say, both the clinical importance and the question of whether the 2-year improvement will last 5 years are uncertain. The results from the phase 2 FORWARD trial (FGF-18 Osteoarthritis Randomized Trial with Administration of Repeated Doses), a dose-finding, 10-site, randomized clinical trial involving patients with symptomatic knee osteoarthritis, were published online October 8 in JAMA.

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now